Welcome to our first pre-close catch-up, which was recorded on March 26, 2025, a new format which replaces our catch-up calls. In this new format, we sum up and repeat relevant topics which were communicated in public as potentially relevant for the upcoming quarter. You might already follow our quarterly wrap-up, where we summarize the most important topics across the board from the roadshows after our earnings release. With this new first episode of our pre-close catch-up, we aim at having everyone on the same page regarding our Q2 fiscal 2025 before we go into silent period. This catch-up will usually be published towards the end of the quarter. Obviously, we are before closing and therefore have no indications on Q2 actuals at this point of time.
Before we start with this, now for the very first time, let me remind you of the Safe Harbor statement on our website for this recording. Let us begin, as usual, with a short statement on currencies. We have seen quite some volatility in currencies this quarter to date, particularly in the US dollar. Therefore, it is too early to tell how translational effects from foreign exchange will be affecting the revenue line and finally playing out for the full quarter. Let me quote our CFO from our Q1 analyst call 2025 earlier this year, talking about Q2. Quote start: "For Q2, we see our fundamentals intact. We expect growth to continue in Q2.
In terms of growth intensity, after our Q1 growth in the upper half of our guidance range for the fiscal year, it would be fair to assume Q2 growth to be around the lower end of the 5-6% range. That means around 5%. For Imaging, growth in Q2 will be more in line with our assumption for the full fiscal year. That means at mid-single digits after the strong start in Q1 with 8%. For Varian, which started in Q1 below its assumed growth trajectory for the full fiscal year, it would be fair to assume that Q2 revenue will be more in the higher single digits. On the margin side in Q2, it's best to assume the adjusted EBIT margin expansion year over year in Imaging and Varian as per the respective assumptions for the full year.
This means in Imaging, low to mid-double-digit basis points margin expansion and in Varian between 50 and 150 basis points margin expansion. We expect in Diagnostics the same dynamics in Q2 or comparable dynamics in Q2 as in Q1. End of quote. We have mentioned in the course of our quarter that we see our fundamentals intact and expect growth to continue in Q2. What should you have in mind going through segment by segment? For Imaging, we outlined that we continue to expect Q2 growth to be more in line with our assumption for the full year. This would mean mid-single digit growth after the strong start in Q1. For Imaging margin in Q2, there was no additional color to the assumption of low to mid-double digits margin expansion for the full year mentioned in the course of the quarter.
For Varian growth in Q2, there was also no additional color mentioned in the course of the quarter. We said that it would be fair to assume higher single-digit growth in Q2 in line with the assumption of higher single-digit growth for the full year, also considering that Varian growth in Q1 was below the growth trajectory. For the Varian margin in Q2, there was no additional color to the assumption of 50-150 basis points margin expansion for the year mentioned in the course of the quarter, albeit we did make clear in discussions post Q1 that Varian would likely be the most exposed segment when it comes to the force-only limited impacts from the current US tariffs on Mexico, Canada, and China. In Diagnostics, we outlined that the dynamics for Q2 were comparable to Q1. This relates both to growth and margin development, i.e., expansion.
As a reminder, year-over-year margin expansion in Q1 was 270 basis points. Advanced Therapies, as the smallest segment, was not separately commented on, but just to remind you of our full year assumptions for the segment, as disclosed in Q4, mid-single digit growth and low to mid-double digit basis points margin expansion. Summarizing again for the group, in terms of the intensity of growth, after group growth in Q1 being in the upper half of our guidance range for the fiscal year, we said that it would be fair to assume growth in Q2 to be around the lower end of the 5-6% range, i.e., around 5%. Let's now move down the P&L. On the line items tax and financial income, there was nothing extraordinary discussed related to Q2.
From a modeling point of view, it may be best to assume for Q2 the respective midpoints and run rates from the underlying assumptions for fiscal year 2025 as disclosed in last Q4. With this, I shall close our first pre-close catch-up. Since it is the first one, we would very much appreciate any feedback from you. If anything remains unclear, the Investor Relations team and I are here to help as long as we have not entered a quiet period. Stay safe, stay healthy. Bye-bye.